Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pituitary ; 21(6): 584-592, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30218242

ABSTRACT

PURPOSE: In most clinical series of Cushing's disease (CD), over 80% of patients are women, many of whom are of reproductive age. The year following pregnancy may be a common time to develop CD. We sought to establish the incidence of CD onset associated with pregnancy. METHODS: A retrospective review was conducted for patients with biochemically-proven CD. Demographics, clinical history, biochemistry, imaging, pathology, and outcomes were reviewed. Pregnancy-associated CD was defined as symptom onset within 1 year of childbirth. RESULTS: Over 10 years, 77 patients including 64 women (84%), with CD underwent endonasal surgery. Of the 64 women, 64% were of reproductive age (15-45 years) at the time of diagnosis, and 11 (27%) met criteria for pregnancy-associated CD. Of these 11 women, median number of pregnancies prior to onset of CD was 2 (range 1-4) compared to zero (range 0-7) for 30 other women with CD onset during reproductive age (p = 0.0024). With an average follow-up of 47 ± 34 months, sustained surgical remission rates for woman with pregnancy-associated CD, other women of reproductive age, and women not of reproductive age were 91%, 80% and 83%, respectively. The average lag-time from symptom onset to diagnosis for women with pregnancy-associated CD was 4 ± 2 years. CONCLUSIONS: In this exploratory study, over one quarter of women of reproductive age with CD appeared to have symptomatic disease onset within 1 year of childbirth. This relatively high rate of pregnancy-associated CD suggests a possible causal relationship related to the stress of pregnancy and pituitary corticotroph hyperactivity in the peripartum period. This possible association suggests a heightened degree of clinical suspicion and biochemical testing for CD may be warranted after childbirth. Further study of this possible link between pregnancy and CD is warranted.


Subject(s)
Pituitary ACTH Hypersecretion/metabolism , Adolescent , Adult , Corticotrophs/metabolism , Corticotrophs/pathology , Female , Humans , Middle Aged , Peripartum Period , Pituitary ACTH Hypersecretion/pathology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Pregnancy , Pregnancy Complications , Retrospective Studies , Young Adult
2.
J Neurosurg ; 118(3): 613-20, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23240699

ABSTRACT

OBJECT: Endoscopy as a visual aid (endoscope assisted) or as the sole visual method (fully endoscopic) is increasingly used in pituitary adenoma surgery. Authors of this study assessed the value of endoscopic visualization for finding and removing residual adenoma after initial microscopic removal. METHODS: Consecutive patients who underwent endoscope-assisted microsurgical removal of pituitary adenoma were included in this study. The utility of the endoscope in finding and removing residual adenoma not visualized by the microscope was noted intraoperatively. After maximal tumor removal under microscopic visualization, surgeries were categorized as to whether additional tumor was removed via endoscopy. Tumor removal and remission rates were also noted. Patients undergoing fully endoscopic tumor removal during this same period were excluded from the study. RESULTS: Over 3 years, 140 patients (41% women, mean age 50 years) underwent endoscope-assisted adenoma removal of 30 endocrine-active microadenomas and 110 macroadenomas (39 endocrine-active, 71 endocrine-inactive); 16% (23/140) of patients had prior surgery. After initial microscopic removal, endoscopy revealed residual tumor in 40% (56/140) of cases and the additional tumor was removed in 36% (50 cases) of these cases. Endoscopy facilitated additional tumor removal in 54% (36/67) of the adenomas measuring ≥ 2 cm in diameter and in 19% (14/73) of the adenomas smaller than 2 cm in diameter (p < 0.0001); additional tumor removal was achieved in 20% (6/30) of the microadenomas. Residual tumor was typically removed from the suprasellar extension and folds of the collapsed diaphragma sellae or along or within the medial cavernous sinus. Overall, 91% of endocrine-inactive tumors were gross-totally or near-totally removed, and 70% of endocrine-active adenomas had early remission. CONCLUSIONS: After microscope-based tumor removal, endoscopic visualization led to additional adenoma removal in over one-third of patients. The panoramic visualization of the endoscope appears to facilitate more complete tumor removal than is possible with the microscope alone. These findings further emphasize the utility of endoscopic visualization in pituitary adenoma surgery. Longer follow-ups and additional case series are needed to determine if endoscopic adenomectomy translates into higher long-term remission rates.


Subject(s)
Adenoma/diagnosis , Adenoma/surgery , Neoplasm, Residual/prevention & control , Neuroendoscopy , Nose , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/surgery , Sphenoid Sinus , Adenoma/complications , Adenoma/pathology , Adult , Aged , Aged, 80 and over , Diabetes Insipidus/etiology , Female , Follow-Up Studies , Humans , Hypopituitarism/etiology , Incidence , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Neuroendoscopy/adverse effects , Neuroendoscopy/methods , Pituitary Neoplasms/complications , Pituitary Neoplasms/pathology , Radiotherapy, Adjuvant , Retrospective Studies , Risk Factors , Stroke/etiology , Treatment Outcome , Vision Disorders/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...